← All stories
Markets
Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring.
The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.
Covered by 1 outlet
All coverage · 1 article